Neramexane

Neramexane is a chemical compound that functions as an NMDA receptor antagonist and nicotinic acetylcholine receptor antagonist. It has been investigated for its potential therapeutic effects in various neurological and psychiatric disorders.
Pharmacology[edit]
Neramexane primarily acts by blocking the NMDA receptor, which is a subtype of glutamate receptor involved in synaptic plasticity and memory function. By inhibiting this receptor, neramexane can reduce excitotoxicity, which is a pathological process where nerve cells are damaged and killed by excessive stimulation by neurotransmitters such as glutamate.
Additionally, neramexane also antagonizes the nicotinic acetylcholine receptor, which plays a role in cognitive processes and neuroprotection. This dual action makes neramexane a compound of interest for conditions where both glutamatergic and cholinergic systems are implicated.
Therapeutic Uses[edit]
Neramexane has been studied for its potential use in treating several conditions, including:
Mechanism of Action[edit]
The mechanism of action of neramexane involves the inhibition of the NMDA receptor and the nicotinic acetylcholine receptor. By blocking these receptors, neramexane can modulate neurotransmitter release and neuronal excitability, which may contribute to its therapeutic effects.
Side Effects[edit]
As with other NMDA receptor antagonists, neramexane may cause side effects such as:
Research and Development[edit]
Neramexane is still under investigation, and its efficacy and safety profile are being evaluated in clinical trials. The outcomes of these studies will determine its potential as a therapeutic agent for various neurological and psychiatric conditions.
See Also[edit]
- NMDA receptor antagonist
- Nicotinic acetylcholine receptor
- Alzheimer's disease
- Parkinson's disease
- Tinnitus
- Chronic pain
- Depression
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian